{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cha HH"],"funding":["Korea Health Industry Development Institute","Ministry of Health and Welfare"],"pagination":["455-459"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8925962"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37(2)"],"pubmed_abstract":["<h4>Background/aims</h4>Data comparing the antibody responses of different coronavirus disease 2019 (COVID-19) vaccine platforms according to dose with natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection-induced antibody responses are limited.<h4>Methods</h4>Blood samples from adult patients with mild and severe COVID-19 and healthcare workers who received ChAdOx1 nCoV-19 vaccine (2nd dose at 12-week intervals) and BNT162b2 vaccine (2nd dose at 3-week intervals) were collected and compared by immunoglobulin G immune responses to SARS-CoV-2 specific spike protein using an in-house-developed enzyme-linked immunosorbent assay.<h4>Results</h4>A total of 53 patients, including 12 and 41 with mild and severe COVID-19, respectively, were analyzed. In addition, a total o"],"journal":["The Korean journal of internal medicine"],"pubmed_title":["Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19."],"pmcid":["PMC8925962"],"funding_grant_id":["HW20C2062"],"pubmed_authors":["Kim SH","Jung J","Kim JY","Bae S","Lim SY","Kwon JS","Cha HH"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.","description":"<h4>Background/aims</h4>Data comparing the antibody responses of different coronavirus disease 2019 (COVID-19) vaccine platforms according to dose with natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection-induced antibody responses are limited.<h4>Methods</h4>Blood samples from adult patients with mild and severe COVID-19 and healthcare workers who received ChAdOx1 nCoV-19 vaccine (2nd dose at 12-week intervals) and BNT162b2 vaccine (2nd dose at 3-week intervals) were collected and compared by immunoglobulin G immune responses to SARS-CoV-2 specific spike protein using an in-house-developed enzyme-linked immunosorbent assay.<h4>Results</h4>A total of 53 patients, including 12 and 41 with mild and severe COVID-19, respectively, were analyzed. In addition, a total o","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T07:44:09.737Z","creation":"2025-04-04T07:44:09.737Z"},"accession":"S-EPMC8925962","cross_references":{"pubmed":["35272444"],"doi":["10.3904/kjim.2021.409"]}}